• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Recipharm to Present Interim Report for the Third Quarter 2016 on November 10

    Chelsea Pratt
    Nov. 07, 2016 03:11AM PST
    Life Science Investing News

    Recipharm will publish its interim report for January-September 2016 on 10 November at 07:45 am CET. The company invites investors, analysts and media to a web conference (in English) on 10 November at 10:00 am CET.

    Recipharm (STO:RECIB) will publish its interim report for January-September 2016 on 10 November at 07:45 am CET. The company invites investors, analysts and media to a web conference (in English) on 10 November at 10:00 am CET, where CEO Thomas Eldered and CFO Björn Westberg will present and comment on the report as well as answer questions.
    The report will be available on Recipharm’s website www.recipharm.com/investor-relations
    from 07:45 am CET the same day and the presentation from the webcast
    will be uploaded during the day on the 10 November.
    To participate in the web conference, please use the below link: https://edge.media-server.com/m/p/prxpzamq
    Questions may be submitted by dialing below telephone numbers or by
    typing them in the Q&A box during the conference. If you don’t wish to
    ask questions by telephone you only need to participate through the link
    above.
    From Sweden: + 46 8 505 963 06
    From Denmark: + 45 354 45597
    From Finland: + 358 9 8171 0317
    From France: + 33 29092 0977
    From Germany: + 49 30 211 510 067
    From India: + 91 226187 51 03
    From Italy: + 39 2 3604 67 98
    From Norway: + 47 235 00 559
    From Portugal: + 35 210 609104
    From Spain: + 34 911 143 608
    From Switzerland: + 41 44 5800083
    From the UK: + 44 203 139 48 30
    From the USA: + 1 718 873 90 77
    Pin code for participants:
    44823539#
    Recipharm AB (publ)
    Corporate identity number 556498-8425
    Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
    00, Fax 46 8 81 87 03
    www.recipharm.com
    This information was brought to you by Cision https://news.cision.com

    germanyindiainterim reportq3 2016
    The Conversation (0)

    Go Deeper

    AI Powered

    Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

    InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

    InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×